Difference between revisions of "Angiocidin"
m |
m |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 43: | Line 43: | ||
| Notes | | Notes | ||
| Cross-linked angiocidin disrupts the tumor ECM making it less permissive for tumor growth. | | Cross-linked angiocidin disrupts the tumor ECM making it less permissive for tumor growth. | ||
| − | + | Angiocidin inhibits tTgase-dependent incorporation of fibronectin into the ECM. | |
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:23, 10 March 2015
| Angiocidin | |
|---|---|
| Substrate peptide name | Angiocidin |
| Synonyms | 26S proteasome non-ATPase regulatory subunit 4 |
| Determination type | In situ |
| Source | Homo sapiens (HUVEC) |
| Subcellular localization | Cytosol/Extracellular matrix |
| Swissprot ID | P55036 |
| Reactive glutamines | Not determined yet |
| Reactive lysines | - |
| Substrate sequence | Not determined yet |
| Structure | 2KDF |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:19931242 |
| Notes | Cross-linked angiocidin disrupts the tumor ECM making it less permissive for tumor growth.
Angiocidin inhibits tTgase-dependent incorporation of fibronectin into the ECM. |
